The relevance of natural compounds in the Alzheimer´s Disease by Loureiro, Joana Angélica de Sousa

















Faculdade Ciências da Saúde 
Universidade Fernando Pessoa 
 
Porto, 2018 












































Faculdade Ciências da Saúde 
Universidade Fernando Pessoa 
 
Porto, 2018 





















Trabalho apresentado à Universidade 
Fernando Pessoa como parte dos requisitos 
para obtenção de grau de Mestre em 
Ciências Farmacêuticas. 





A incidência da doença de Alzheimer (DA), uma doença neurodegenerativa, é 
promovida pelo aumento da idade. Esta doença afeta a memória e outras funções 
cognitivas com intensidade suficiente para produzir uma perda funcional. É a causa 
mais comum de demência em idosos. O aumento contínuo da incidência da DA exige o 
desenvolvimento urgente de uma terapêutica. Embora os estudos sobre essa doença 
estejam a avançar rapidamente, até o momento, poucos medicamentos para retardar a 
progressão da doença estão disponíveis no mercado. Nas últimas décadas, vários 
compostos com diversas atividades farmacológicas extraídas de frutas, vegetais e ervas 
demonstraram ter uma potencial eficácia contra a DA por meio de múltiplas alterações 
patológicas da doença. A diversidade de compostos bioativos presentes nesses produtos 


























The incidence of Alzheimer’s disease (AD), a neurodegenerative disease, is promoted 
by the increase of the age. This disease affects the memory and other cognitive 
functions with sufficient intensity to produce a functional loss, and it is the most 
common cause of dementia in the elderly. The continuous increase in the incidence of 
AD demands the urgent development of new therapies. Although, studies on this 
disease are advancing quickly, until the moment just few drugs to delay the progression 
of the disease are available for the patients. In recent decades, a number of compounds 
with diverse pharmacological activities extracted from fruits, vegetables and herbs 
demonstrated to have potential efficacies against AD via targeting multiple pathological 
changes of this disease. The diverse array of bioactive compounds presented in these 
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Aβ - Amyloid beta peptide  
APP - Amyloid precursor protein  
BBB – Blood-brain barrier  
COX - Cyclo-oxygenase  
DA – Doença de Alzheimer´s 
DHA - Docosahexanoic acid 
DNA - Deoxyribonucleic acid  
EGCG - Epigallocatechin gallate 
NFTs - Neurofibrillary tangles  
NSAIDs - Non-steroidal anti-inflammatory drugs 
PS - Presenilin protein 
RNS - Reactive nitrogen species  
























The increase of the age promotes the incidence of neurodegenerative diseases. These 
diseases destabilize significantly the memory and other cognitive functions with 
sufficient intensity to produce a functional loss, such as carrying out everyday activities 
or recognizing people and places (Brookmeyer, Johnson et al. 2007). 
Alzheimer’s disease (AD) is known as the most important neurodegenerative disease 
and the most common cause of dementia among the elderly, counting with around 70% 
of dementia cases worldwide (Alzheimer, Stelzmann et al. 1995, LaFerla and Oddo 
2005, Castellani, Rolston et al. 2010, Kumar, Singh et al. 2015).  
Based on empirical observations, natural compounds were the first medicines available, 
and were used for a long time (Lahlou 2007, Ganesan 2008). The study of novel drug 
candidates has revealed that natural products have a giant potential to become drug 
leads with neuroprotective activity. Given that the creation of big quantities of 
compounds isolated from natural products is extremely protracted and expensive, there 
is a great interest for the mixtures of compounds obtained from extracts of plant 
material or from microbial broths (Harvey 2008). 
A diversity of natural compounds has been reported to be effective for the prevention 
and cure of AD. The potential of natural products for the inhibition of amyloid peptides 
aggregation in vitro and for the delay of progression of the disease in animal models is 
supported by various experimental studies. Several fruits, plants, animals, marine 
organisms or microorganisms have important bioactive compounds essential for the 
prevention and cure of various diseases without undesirable side effects, including AD.  
In this review, a detailed description of natural compounds with beneficial effects in AD 
and their mechanisms of action is reported and sorted by order by alphabet order. The 
use of natural compounds is a promising approach for AD therapy. 
  




II. Relevant approaches to treat Alzheimer´s Disease 
Nowadays none medications appears to be able to cure AD or to stop the progression of 
disease (Clark and Karlawish 2003, Scarpini, Scheltens et al. 2003, Cummings 2004, 
Barage and Sonawane 2015). 
So, there is a tremendous medical need for the development of novel therapeutic 
strategies that target the underlying pathogenic mechanisms in AD. It is obvious from 
the literature that amyloid beta peptide (Aβ) plays the main role in the pathogenesis of 
AD. Therefore, according to the amyloid cascade hypothesis novel therapeutic strategies 
that inhibit Aβ production/aggregation or to increase Aβ clearance from the brain or 
prevent the formation of the presumed neurotoxic oligomeric Aβ species are predicted 
to stop or retard the progression of neurodegeneration and dementia in AD (Blennow, 
de Leon et al. 2006, Klafki, Staufenbiel et al. 2006). Others strategies to treat AD are 
being developed such as tau based therapeutics, the use of anti-inflammatory drugs and 
the use of antioxidants. 
Secretase modulators: The most direct approach in anti-amyloid therapy is the decrease 
of Aβ1-42 production.  Aβ derives from the proteolytic cleavage of amyloid precursor 
protein (APP), by the sequential action of two proteases: β- and γ-secretases 
(amyloidogenic pathway). A third protease, α-secretase, which competes with β-
secretase for the APP substrate, can preclude the Aβ production by cleaving the peptide 
in two (non-amyloidogenic pathway). Thus, this scenario suggests three strategies to 
reduce Aβ that have been intensely studied for more than a decade: the inhibition of β 
and γ-secretases or the stimulation of α-secretase (Verdile, Fuller et al. 2004, Citron 
2010). 
Despite the development in production of γ-secretase inhibitors, there are many issues 
related with their potential effects on Notch signaling, effects on known or unidentified 
γ-secretase substrates, and the effects of the accumulation of potentially neurotoxic APP 
C-terminal fragments as a result of inhibiting γ-secretase (Hadland, Manley et al. 2001). 
For these reasons, it is believed that β-secretase is a better therapeutic target because do 
not produce Aβ and do not have clear pathological phenotypes (Luo, Bolon et al. 2001). 
Therefore, β-secretase is a major therapeutic target for the development of inhibitor 




drugs to reduce brain Aβ concentrations (Ballard, Gauthier et al. 2011, Barage and 
Sonawane 2015). Regarding α-secretase, this protease cleaves APP in the 
transmembrane region, within the Aβ domain of the APP releasing soluble APP which 
has neuroprotective effects and improves the memory (Barage and Sonawane 2015). 
Thus, drugs that stimulate the activity of α-secretase can change APP processing 
towards the non-amyloidogenic pathway impeding the Aβ formation which is 
considered a therapeutic approach for AD (Blennow, de Leon et al. 2006, Fahrenholz 
2007). 
Inhibition of Aβ aggregation or fibrillation: The proteolytic cleavage of APP, by the 
sequential action of β- and γ-secretases releases Aβ peptide monomers that initially 
have α-helix conformation followed by extensive conformational transitions from α-
helix to β-sheet. Aβ monomers, in particular Aβ1-42, rapidly form self-aggregates to 
produce oligomers aggregates that are thought to initiate the pathogenic cascade. Then, 
oligomers aggregate in protofibrils, fibrils and finally develop the Aβ plaques 
(Kirkitadze, Condron et al. 2001, Xu, Shen et al. 2005, Walsh and Selkoe 2007, 
Ahmed, Davis et al. 2010). Initially, it was assumed that only Aβ that had aggregated 
into the fibrils that constitute the Aβ plaques would exert toxic effects. However, in 
recent years studies have suggested that the formation of oligomers rather than insoluble 
amyloid plaques may play an essential role in the AD neurodegenerative cascade 
(Arendt 2009). It is believed that Aβ oligomers can be more toxic than mature fibrils by 
inducing synaptic dysfunction (Walsh and Selkoe 2007, Shankar, Li et al. 2008, 
Ballard, Gauthier et al. 2011). Promising approaches for the development of small-
molecule drugs that interact with the Aβ, blocking the interactions Aβ–Aβ represents 
another attractive approach. These molecules prevent the formation of toxic Aβ 
oligomers. That way, this molecules that could prevent or treat AD (Klafki, Staufenbiel 
et al. 2006). 
Aβ degradation and clearance: The imbalance between production and clearance of the 
Aβ peptide is responsible for pathological events in AD (Kurz and Perneczky 2011). 
The augmented level of Aβ peptides within the brain is caused by the excess of 
production or by deficient clearance of Aβ peptide (Bates, Verdile et al. 2009). Several 
causes can reduce the clearance of Aβ peptide such as increased aggregation, imperfect 




degradation, troubled transport across the blood-brain barrier (BBB) or inefficient 
peripheral removal of the peptide (Mawuenyega, Sigurdson et al. 2010, Sagare, Bell et 
al. 2012). That way over the past several years these mechanisms have been targeted for 
several studies (Tanzi, Moir et al. 2004, Kurz and Perneczky 2011). 
Immunotherapy: In the last years, Aβ immunotherapy has become one of the most 
promising areas in research of AD, through either active Aβ peptide vaccination or 
passive infusion of anti-Aβ monoclonal antibodies (Solomon, Koppel et al. 1997, 
Schenk, Barbour et al. 1999, Bard, Cannon et al. 2000). The immunotherapy seems to 
be one promising approach for preventing and treating AD. It is believed that the use of 
antibodies against Aβ peptide clears Aβ deposits (Alves, Correia et al. 2012). 
In the first study, the importance of immunotherapy through the active immunization in 
AD transgenic mice was studied and the results demonstrated an attenuated deposition 
of Aβ and neutralization of Aβ oligomers, blocking the toxic effects of Aβ on cells 
(Solomon, Koppel et al. 1997, Schenk, Barbour et al. 1999, Hartman, Izumi et al. 2005, 
Klyubin, Walsh et al. 2005). The authors proposed that Aβ immunization stimulates a 
highly specific immune response to clear Aβ, reducing the pathology in the animal 
model (Schenk, Barbour et al. 1999). Sustaining this hypothesis, antibodies can block 
and even reverse Aβ aggregation and toxicity in vitro (Solomon, Koppel et al. 1997, 
Frenkel, Katz et al. 2000, Du, Wei et al. 2003). Additionally, Aβ immunization shown 
the decrease a variety of aspects of the amyloid associated pathology including neuritic 
dystrophy, synaptic degeneration and tau accumulation (Lombardo, Stern et al. 2003, 
Oddo, Billings et al. 2004, Brendza, Bacskai et al. 2005, Buttini, Masliah et al. 2005). 
Comparable results were obtained using passive immunisation with antibodies against 
Aβ (Bard, Cannon et al. 2000).  
There is some skepticism about how this approach works, because only a small quantity 
of antibody crosses the BBB. Four models of antibody-mediated amyloid clearance 
were proposed. The first model - microglia mediated - suggests that a small amount of 
amyloid-specific antibodies reaches amyloid deposits in the brain, triggering a 
phagocytic response by microglia. In the second model - direct resolution - amyloid-
specific antibodies interact with amyloid deposits in the brain. The third model - 




peripheral sink - suggests that amyloid-specific antibodies act as a peripheral sink for 
soluble Aβ species, leading ultimately to the resolution of brain deposits by pulling 
soluble Aβ into the periphery, where it is quickly cleared. In the fourth and last model - 
blockade of toxic oligomers - amyloid-specific antibodies rapidly bind to Aβ oligomers, 
inhibiting their toxic effects without immediate effect on amyloid load (Citron 2010). 
Inhibition of tau aggregation or tau hyperphosphorylation: Tau, a microtubule-
associated protein responsible for the assembly and stability of microtubules in the 
neuronal cell and for axoplasmatic transport, is the major constituent of neurofibrillary 
tangles (NFTs). These characteristic structures observed in AD neurons are constituted 
by tau hyperphosphorylated (Lee, Goedert et al. 2001, Gotz, Schild et al. 2004, 
Goedert, Klug et al. 2006, Small and Duff 2008, Herrup 2010, Alves, Correia et al. 
2012). Tau is a soluble protein, but insoluble aggregates are produced during the 
formation of NFTs, which disrupt the structure and function of the neuron. Initially, tau 
monomers bind and form oligomers, which then aggregate into a β-sheet before form 
the NFTs (Hardy and Selkoe 2002, Meraz-Ríos, León et al. 2010, Ballard, Gauthier et 
al. 2011). Studies with human AD patients proved that the severity of dementia is 
strongly connected with NFTs density (Wilcock and Esiri 1982, Arriagada, Growdon et 
al. 1992, Nagy, Jobst et al. 1996). 
Thus, substances that can inhibit tau aggregation or the blockade of tau 
hyperphosphorylation can to be a potential treatment strategy, protecting the neurons 
from neurofibrillary degeneration (Chirita, Necula et al. 2004, Pickhardt, Gazova et al. 
2005, Lee and Trojanowski 2006, Schneider and Mandelkow 2008). 
Anti-inflammatory drugs: Induction of inflammatory responses is known to play an 
essential role in the progression of AD, and it is proposed as a mechanism by which Aβ 
could modulate its toxic effects. The insoluble Aβ peptides deposits and NFTs provide 
evident stimuli for inflammation (Wenk 2003). Several studies showed that Aβ 
stimulates macrophages and microglia and induces the release of cytokines. Thus, anti-
inflammatory drugs may be beneficial in slowing the rate of neurodegeneration in AD 
(Clippingdale, Wade et al. 2001). The anti-inflammatory drugs can be an attractive 
target therapeutic option because the targeting inflammatory cascade in AD could 




decrease damaging effects and stimulate clearance of abnormal protein (Schott and 
Revesz 2013). 
A large amount of epidemiological studies proposes that the risk of the AD in patients is 
reduced when treated with non-steroidal anti-inflammatory drugs (NSAIDs) (Aisen 
2002). Evidence from multiple studies showed that risk reduction occurs in AD of 
approximately 50% when the use of NSAIDs is made a long-term (Wyss-Coray 2006). 
High concentrations of numerous NSAIDs show the decrease of Aβ1-42 in AD transgenic 
mice without affecting Notch cleavage, while simultaneously the production of smaller 
Aβ isoforms that are expected to be less prone to aggregation than Aβ1-42 increase 
(Weggen, Eriksen et al. 2001). This reduction in Aβ levels may be caused by either 
inhibition of cyclo-oxygenase (COX) or by a direct effect on γ-secretase (Weggen, 
Eriksen et al. 2001, Eriksen, Sagi et al. 2003). One in vitro study has revealed that 
NSAIDs do not modify the total levels of Aβ produced but rather shift cleavage from 
Aβ1-42 to a shorter 38 amino acid form (Aβ1-38), suggesting that the activity of γ-
secretase cleavage is altered in response to NSAIDs. Despite the role of Aβ1-38 in AD 
pathogenesis to be unknown yet, it is well accepted that the longer Aβ is more 
amyloidogenic, such as the case of Aβ1-42. Thus, this therapeutic approach warrants 
further investigation (Weggen, Eriksen et al. 2001). 
Antioxidants: The intensification of oxidative stress related with AD can play a 
significant role in the neurodegeneration of neurons. Thus, antioxidants have been 










III. Natural compounds and their effects on Alzheimer´s Disease 
A natural product is defined as being a chemical compound or substance that is 
produced by natural sources found in nature including plants, animals, marine 
organisms or microorganisms, that typically has a pharmacological or biological 
properties useful in pharmaceutical drug discovery. 
Natural product and natural extracts were the first medicines applied in the empirical 
treatment of different type of diseases. The discovering of new therapeutic molecules 
demonstrates that natural products have a huge potential in the treatment of an 
enormous variety of pathologies. 
The most studied compounds were presented below and listed in table 1. 
Apigenin: Apigenin (4’,5,7-tetrahydroxyflavone) is a flavonoid and a 
pharmacologically active agent that can be isolated from several plants, herbs, fruits and 
vegetables. Apigenin is particularly abundant in the ligulate flowers of the chamomile 
plant (around 68% of total flavonoids is apigenin) and found in smaller concentrations 
in other sources such as cabbage, celery, parsley and bell pepper (McKay and Blumberg 
2006, Shukla and Gupta 2010). Several studies have demonstrated that apigenin exhibits 
a diversity of biological effects, including anti-inflammatory and antioxidant (Panes, 
Gerritsen et al. 1996, Gupta, Afaq et al. 2001, Jin, Qian et al. 2009, Balez, Steiner et al. 
2016). Apigenin has been the subject of interests in recent years as a beneficial and 
health promoting agent due to the several biological effects and its low intrinsic toxicity 
(Choi, Islam et al. 2014). One study with apigenin showed that this compound can 
affect APP processing through the inhibition of β-secretase thereby preventing Aβ 
deposition and decrease the insoluble Aβ levels (Zhao, Wang et al. 2013). It is a potent 
chelating agent that reduces the metal ions participating in radical reactions and 
therefore reduces the creation of free radicals. Furthermore, apigenin could serve as an 
antioxidant to eliminate free radicals such as oxygen, nitric oxide, and superoxide anion 
(Sugihara, Arakawa et al. 1999). Evidences have showed that apigenin protects rat 
cortical neurons against Aβ-induced neurotoxicity (Butterfield, Reed et al. 2007).  




Asiatic acid: Asiatic acid is a pentacyclic triterpene isolated from a variety of plants, 
including Centella asiatica. A study with asiatic acid showed that this compound 
significantly affects APP processing through the inhibition of β-secretase and the 
increase of α-secretase (non-amyloidogenic pathway). The direct inhibition of β-
secretase is known to increase non-amyloidogenic processing. In addition, the study 
suggests that the asiatic acid is able to activate Aβ clearance mechanisms (Patil, Maki et 
al. 2010). A significant decrease in Aβ was detectable in PSAPP mice (Dhanasekaran, 
Holcomb et al. 2009). A recent study affirmed that the extract of asiatic acid attenuated 
Aβ-associated behavioral abnormalities in the Tg2576 mouse, a murine model of AD. 
In vitro, this natural compound protected SH-SY5Y cells and MC65 human 
neuroblastoma cells from toxicity induced by exogenously added and endogenously 
generated Aβ, respectively (Soumyanath, Zhong et al. 2012). Asiatic acid improves 
learning and memory in vivo, with several studies suggesting that antioxidant 
mechanisms explain cognitive benefits (Gupta, Veerendra Kumar et al. 2003, 
Gnanapragasam, Ebenezar et al. 2004). Asiatic acid reduces brain oxidative stress 
including in AD animal models (male Wistar rats), scavenges free radicals, reduces lipid 
peroxidation and protects against deoxyribonucleic acid (DNA) damage (Gupta, 
Veerendra Kumar et al. 2003, Veerendra Kumar and Gupta 2003, Shinomol and 
Muralidhara 2008, Dhanasekaran, Holcomb et al. 2009). 
Baicalein: Baicalein is a flavonoid extracted from the roots of chinese herbal medicine 
Scutellaria baicalensis (Heo, Kim et al. 2004, Lu, Ardah et al. 2011, Zhang, Obregon et 
al. 2013). Some studies show the importance of this compound in AD. Studies have 
suggested that baicalein can reduce the cytotoxicity of Aβ, probably by a decrease of 
oxidative stress, through inhibition of reactive oxygen species production (Heo, Kim et 
al. 2004, Choi, Choi et al. 2010, Moslehi, Meshkini et al. 2012, Bend, Xia et al. 2015). 
Baicalein inhibited Aβ-induced membrane damage and neurotoxicity in a dose 
dependent pattern (Heo, Kim et al. 2004). The effect of baicalein on Aβ aggregation and 
toxicity was also studied. The results proved that baicalein could inhibit Aβ fibrillation 
and oligomerisation, disaggregate pre-formed Aβ amyloid fibrils and prevent Aβ fibril-
induced toxicity (Lu, Ardah et al. 2011). Existing Aβ fibrils are disaggregated by 
baicalein, suggesting that the depolymerization of Aβ fibrils happened (Song, Wang et 




al. 2012). A study also suggests that baicalein promotes a non-amyloidogenic pathway 
of APP processing, by the increase of α-secretase and the reduction of β-secretase 
activity. Thereby, it reduces the Aβ production. Also, it was observed that baicalein is 
able to prevent phosphorylation of tau in APP/PS1 mice and improve cognitive 
performance (Zhang, Obregon et al. 2013, Wei, Tang et al. 2014, Gu, Xu et al. 2016).   
Berberine: Berberine is a natural isoquinoline alkaloid isolated from Rhizoma coptidis, 
an important herb widely used in Chinese herbal medicine (Asai, Iwata et al. 2007, Ji 
and Shen 2011). Some studies have been conducted to verify its importance in AD. 
Evidences suggest that berberine reduces extracellular Aβ levels by the alteration in 
APP processing (Asai, Iwata et al. 2007, Durairajan, Liu et al. 2012). More specifically, 
berberine reduce the Aβ production by inhibition of β-secretase expression in a rabbit 
model of AD (male New Zealand white rabbits) (Zhu, Wu et al. 2011, Zhu, Wu et al. 
2011, Panahi, Mahmoudian et al. 2013, Huang, Jiang et al. 2017). The treatment of 
TgCRND8 mice, a well-established transgenic mouse model of AD, with berberine also 
inhibited significantly the hyperphosphorylation of APP and tau (Yu, Tian et al. 2011, 
Durairajan, Liu et al. 2012). Also, berberine has been also demonstrates to be 
advantageous to AD through their anti-inflammation properties, antioxidative effects 
scavenging reactive oxygen species (ROS) and reactive nitrogen species (RNS) and 
suppressing lipid peroxidation involved in Aβ formation and accumulation (Rackova, 
Majekova et al. 2004, Yokozawa, Ishida et al. 2004, Asai, Iwata et al. 2007, Xu and 
Zhou 2010, Yu, Tian et al. 2011, Jia, Liu et al. 2012, Abd El-Wahab, Ghareeb et al. 
2013, Xu, Zhang et al. 2013, Das, Mazumder et al. 2015). A recent work finds that 
berberine could promote Aβ clearance and inhibit Aβ production in the triple-transgenic 
mouse model of AD (3×Tg-AD). A reduction of extracellular and intracellular Aβ, APP 
levels and Aβ plaque deposition in the hippocampus of AD mice was observed (Huang, 
Jiang et al. 2017). 
Caffeine: Caffeine is a methylxanthine and probably the most widely consumed 
psychoactive substance in the world. The principal source of caffeine is the coffee bean, 
from which coffee is brewed (Arendash, Schleif et al. 2006). Caffeine is present in 
numerous dietary sources consumed around the world, including coffee, tea, cocoa 
beverages, candy bars, and soft drinks (Nehlig 1999). Epidemiological studies have 




shown that caffeine consumption has an inverse relation with the incidence of AD 
(Maia and de Mendonca 2002). The long-term ingestion of caffeine is directly related 
with improved cognitive performance and memory. This benefic effect may be due to 
reduced expression of presenilin (PS)1, β-secretase and γ-secretase, indicating that 
decreased Aβ production can be a mechanism of caffeine cognitive protection 
(Arendash, Schleif et al. 2006, Arendash, Mori et al. 2009). An epidemiological study 
suggested that caffeine consumption resulted in lower cortical and hippocampal Aβ 
level, including Aβ 1–40 and Aβ 1–42 (Arendash, Schleif et al. 2006, Arendash, Mori et al. 
2009, Cao, Cirrito et al. 2009, Chu, Chang et al. 2012, Soliman, Geiger et al. 2017). 
The caffeine administration significantly reduced the Aβ1–42 levels in cortex and 
hippocampus, 51 and 59%, respectively, when compared to controls. Similarly, Aβ1–40 
levels reduced 25% in cortex and 37% in hippocampus after the caffeine treatment 
(Arendash, Mori et al. 2009). The reduction of Aβ levels can be due to the ability of 
caffeine to inhibit the formation of β-sheets (Sharma, Kalita et al. 2016). Caffeine has 
been suggested as anti-inflammatory and antioxidant compound (Brothers, Marchalant 
et al. 2010, Prasanthi, Dasari et al. 2010, Prasanthi, Dasari et al. 2010, Ruiz-Medina, 
Pinto-Xavier et al. 2013, Ullah, Ali et al. 2015). In addition to the processes mentioned 
above, caffeine can protect against AD pathology through its antioxidant properties. The 
reduction in Aβ levels after the administration caffeine can be associated with reduction 
in oxidative stress (Prasanthi, Dasari et al. 2010). The improved memory caused by 
caffeine can be also associated with reduced hippocampal tau phosphorylation and 
proteolytic fragments (Prasanthi, Dasari et al. 2010, Prasanthi, Dasari et al. 2010, 
Currais, Kato et al. 2011, Laurent, Eddarkaoui et al. 2014). Besides, a study 
demonstrated that caffeine can enhance brain Aβ clearance, and this effect could 
explain, in part, the protective effect of caffeine against AD (Qosa, Abuznait et al. 
2012).  
Colostrinin: Colostrinin is a mixture of proline-rich polypeptides derived from 
colostrums. This is a form of milk produced by mammary glands in the final step of the 
pregnancy (Popik, Bobula et al. 1999). In vitro evidences have revealed that colostrinin 
inhibits Aβ aggregation and the formation of short Aβ fibrils. Also, it simplifies the 
disassembly of existing aggregates by disrupting β-sheet bonding (Popik, Bobula et al. 
1999, Schuster, Rajendran et al. 2005). Additionally, a study demonstrates that 




colostrinin can solubilize Aβ fibrils reducing de fibril formation (Bourhim, Kruzel et al. 
2007). Colostrinin facilitated spatial learning and helped to maintain cognitive and daily 
functions in patients with mild to moderate AD (Popik, Bobula et al. 1999, Schuster, 
Rajendran et al. 2005). In addition, a study showed that colostrinin alters gene 
expression of molecular networks concerned in APP synthesis, tau phosphorylation and 
increased levels of enzymes that proteolitically eliminate Aβ (Szaniszlo, German et al. 
2009). Moreover, studies have revealed that colostrinin is an oxidative stress modulator 
and decreased the expression of inflammatory chemokines and cytokines (Boldogh and 
Kruzel 2008, Szaniszlo, German et al. 2009). Studies on cultured cells demonstrated 
that colostrinin modulates intracellular levels of ROS, via regulation of glutathione 
metabolism, activity of antioxidant enzymes and mitochondria function (Boldogh and 
Kruzel 2008). 
Crocin: Crocin is the main carotenoid present in the saffron flower (Crocus sativus) 
stigma and it has many medicinal properties. An experiment showed that crocin 
inhibited the fibril formation due to their ability to bind to the Aβ hydrophobic regions 
(Papandreou, Kanakis et al. 2006). Crocin decreased the number of fibrils formed and 
significantly reduced the average fibril length of Aβ1-40 (Ghahghaei, Bathaie et al. 
2012). An additional study affirmed that the anti-amyloidogenic effect of crocin may be 
exerted not only by the inhibition of Aβ fibril formation but also by the disruption of Aβ 
aggregates (Ghahghaei, Bathaie et al. 2013). Besides, other studies affirmed that the 
beneficial effects of crocin on memory processing might be attributed to its favorable 
antioxidant and anti-inflammatory effects (Nam, Park et al. 2010, Naghizadeh, 
Mansouri et al. 2013, Finley and Gao 2017).  
Curcumin: Curcumin, or diferuloylmethane, is a well-known active ingredient used in 
the traditional herbal remedy and Indian cuisine. It is isolated from the root of Curcuma 
longa L. (Ak and Gulcin 2008). Curcumin may represent a promising approach for 
preventing or treating AD because it has a number of beneficial properties with 
neuroprotective efficacy, including anti-inflammatory, antioxidant, and anti-fibrilogenic 
activities. In vivo and in vitro studies demonstrated the ability of curcumin to inhibit the 
generation of Aβ, formation of Aβ oligomers, Aβ fibrils, formation of amyloid plaques, 
and Aβ aggregation, but also destabilizing preformed Aβ fibrils (Ono, Hasegawa et al. 




2004, Yang, Lim et al. 2005, Zhang, Si et al. 2010, Zhang, Zhang et al. 2011, Caesar, 
Jonson et al. 2012, Huang, Chang et al. 2012, Zhang, Sun et al. 2013, Wang, Su et al. 
2014, Wang, Xu et al. 2015, Thapa, Jett et al. 2016). Besides that, curcumin reduced Aβ 
deposition improving cognitive performance in a transgenic animal model of AD 
(5XFAD) (McClure, Ong et al. 2017). Curcumin treatment was found to decrease Aβ 
production by attenuating the maturation of APP in the secretory pathway (Lim, Chu et 
al. 2001, Zhang, Browne et al. 2010). In addition, it was reported that curcumin 
suppressed the up-regulation of APP, β and γ-secretase levels and also decreased PS1 
(Lin, Chen et al. 2008, Shimmyo, Kihara et al. 2008, Zhang, Browne et al. 2010, 
Zhang, Si et al. 2010, Xiong, Hongmei et al. 2011, Zhang, Zhang et al. 2011, Zhang, 
Sun et al. 2013, Wang, Su et al. 2014). A recent research showed that curcumin 
administration dramatically reduced Aβ production by downregulating β-secretase, 
preventing synaptic degradation, and improving spatial learning and memory 
impairment of 5×FAD mice (Zheng, Dai et al. 2017). On the other hand, curcumin 
decrease tau hyperphosphorylation (Park, Kim et al. 2008, Lin, Yu et al. 2013). Several 
other beneficial effects have been attributed to curcumin, including anti-inflammatory 
and antioxidant properties (Lim, Chu et al. 2001, Aggarwal, Kumar et al. 2003, 
Shimmyo, Kihara et al. 2008, Ray and Lahiri 2009, Huang, Chang et al. 2012, Shi, 
Zheng et al. 2015, Yang, Liang et al. 2015, Huang, Zheng et al. 2016, Uǧuz, Öz et al. 
2016).   
Docosahexaenoic acid: Docosahexanoic acid (DHA) is an essential n-3 
polyunsaturated fatty acid found predominantly in marine fish and algae. This 
polyunsaturated fatty acid is also found in the central nervous system, synaptic system 
and other cellular membranes. Several epidemiological and in vivo studies have been 
shown that DHA has protective effects against AD and cognitive alterations. A study 
suggested that DHA have an antioxidant activity because it suppressed the increase in 
lipid peroxide and ROS levels in the cerebral cortex and hippocampus of the AD model 
rats (Hashimoto, Hossain et al. 2002, Cole and Frautschy 2006, De Wilde, Van Der 
Beek et al. 2010, Hashimoto, Hossain et al. 2015). Some experiments have 
demonstrated that DHA administration reduces amyloidogenic processing by decreasing 
β- and γ-secretase activity and increases the stability of α-secretase resulting in 




increased non-amyloidogenic APP processing reduced amounts of Aβ1-42 (Lim, Calon et 
al. 2005, Sahlin, Pettersson et al. 2007, Grimm, Kuchenbecker et al. 2011). In addition, 
DHA reduced the levels of Aβ oligomeric and at micellar concentrations stabilize 
soluble protofibrils hindering their conversion to insoluble fibrils through reducing of 
Aβ fibrillation (Johansson, Garlind et al. 2007, Hashimoto, Shahdat et al. 2008, 
Hashimoto, Shahdat et al. 2009, Hossain, Hashimoto et al. 2009). Results clearly 
indicated that DHA inhibited Aβ1-42 fibril formation with a concomitant reduction in the 
levels of soluble Aβ1-42 oligomers. The polymerization into fibrils of preformed 
oligomers treated with DHA was inhibited, indicating that DHA not only obstructs their 
formation but also inhibits their transformation into fibrils (Hossain, Hashimoto et al. 
2009). Image analysis of brain sections revealed that overall plaque burden was 
significantly reduced in 40.3%, with the largest reductions (40-50%) in the 
hippocampus and parietal cortex (Lim, Calon et al. 2005).  Besides that, DHA reduces 
the secreted Aβ levels and increases Aβ degradation (De Wilde, Van Der Beek et al. 
2010, Hashimoto, Hossain et al. 2015) by affecting insulin-degrading enzyme, the 
major Aβ-degrading enzyme secreted into the extracellular space of neuronal and 
microglial cells (Grimm, Mett et al. 2016). 
Epigallocatechin gallate: Epigallocatechin gallate (EGCG) is a major polyphenolic 
compound present in green tea (Camellia sinensis). Several studies have proved that 
EGCG exerts neuroprotective actions. Studies showed that EGCG promotes cleavage of 
αAPP, increasing in six times the αAPP release. These cleavage events are associated 
with elevated α-secretase activity and decreases β- and γ-secretase activities, which lead 
to the reduction of Aβ levels and plaques in brain (Jeon, Bae et al. 2003, Rezai-Zadeh, 
Shytle et al. 2005, Rezai-Zadeh, Shytle et al. 2005, Shimmyo, Kihara et al. 2008, Lee, 
Lee et al. 2009, Lee, Yuk et al. 2009, Zhang, Li et al. 2017). Moreover, EGCG 
inhibited the Aβ fibrillation in vitro by directly binding to the natively unfolded 
polypeptides and preventing their conversion into toxic species (Ehrnhoefer, Bieschke 
et al. 2008). In addition, EGCG inhibited Aβ oligomerization in transgenic 
Caenorhabditis elegans and fibril formation, disassembles preformed Aβ fibrils, 
converting large and mature Aβ fibrils into smaller and modulates tau 
hyperphosphorylation in transgenic mice (Rezai-Zadeh, Arendash et al. 2008, Hauber, 




Hohenberg et al. 2009, Abbas and Wink 2010, Harvey, Musgrave et al. 2011). EGCG 
has the ability to inhibits the aggregation of tau into toxic oligomers and to increases the 
clearance of phosphorylated tau species (Wobst, Sharma et al. 2015, Chesser, Ganeshan 
et al. 2016). Lastly, EGCG has also been reported to exhibit potent antioxidant (Jeong, 
Kim et al. 2004, Kim, Lee et al. 2009, Biasibetti, Tramontina et al. 2013, Zhang, Li et 
al. 2017) and anti-inflammatory properties (Lee, Yuk et al. 2009, Lee, Choi et al. 2013, 
Cheng-Chung Wei, Huang et al. 2016).  
Ferulic acid: Ferulic acid is a ubiquitous phenolic compound found in several fruits and 
vegetables. Ferulic acid is a naturally occurring antioxidants useful in therapeutic 
methodology against AD (Kanski, Aksenova et al. 2002, Kanski, Aksenova et al. 2002, 
Picone, Nuzzo et al. 2013, Maruf, Lip et al. 2015, Tsai, Wu et al. 2015, Shen, Zhang et 
al. 2016). Ferulic acid has the ability to inhibit Aβ production through the decreasing of 
β-secretase activity reducing amyloidogenic APP proteolysis (Ono, Hirohata et al. 2005, 
Mori, Koyama et al. 2013). The inhibition of the β-sheets that are required for the Aβ1-42 
monomer-to-oligomer transition was also observed, inhibiting the Aβ1-42 aggregation 
(Cui, Zhang et al. 2013, Zhang, Cui et al. 2013). Amyloid deposition was also reduced 
with ferulic acid in a transgenic amyloid precursor protein (APP)swe/presenilin 1 
(PS1)dE9 (APP/PS1) mouse model of AD (Yan, Jung et al. 2013). Besides, this 
compound destabilized and disrupted preformed Aβ fibrils (Ono, Hirohata et al. 2005). 
Fisetin: Fisetin is a flavonoid found in plants such as the Japanese fruit wax tree (Rhus 
succedanea), and in very small amounts in strawberries, tomatoes, onions and other 
foods. This compound has been reported as inhibitor of Aβ aggregation, thereby 
inhibiting Aβ fibril formation (Akaishi, Morimoto et al. 2008, Akaishi, Morimoto et al. 
2008). Treatment of cortical cells or primary neurons with fisetin resulted in significant 
decreases in the levels of phosphorylated tau (Kim, Choi et al. 2016). Furthermore, 
fisetin has been suggested as an antioxidant and anti-inflammatory which makes this 
flavonoid an important compound for the AD prevention (Zheng, Ock et al. 2008, 
Maher 2009, Ahmad, Ali et al. 2017). 
Galantamine: Galantamine is produced by Galanthus woronowii Losinsk., some 
species of Narcissus and Leucojum aestivum. A study showed that galantamine may be 




implicated in modifying AD pathophysiological mechanisms by reduces Aβ deposition, 
neuroinflammation, inhibiting Aβ aggregation, and facilitating Aβ clearance (Matharu, 
Gibson et al. 2009, Takata, Kitamura et al. 2010, Wu, Zhao et al. 2015). Antioxidant 
activity of galantamine was also proven (Melo, Sousa et al. 2009, Tsvetkova, 
Obreshkova et al. 2013). Results strongly support that galantamine improves cognitive 
and behavioral symptoms in AD due to its capacity to delay Aβ plaque formation in an 
AD mouse model (5XFAD) (Bhattacharya, Haertel et al. 2014). Additionally, 
galantamine binding to Aβ peptide dimer leads to a significant conformational change 
that disrupts interactions between individual β-strands and promotes a nontoxic 
conformation of Aβ to prevent the formation of neurotoxic oligomers (Rao, Mohamed 
et al. 2013). On the other hand, galantamine reduces Aβ production by inhibiting β-
secretase, stimulating the non-amyloidogenic pathway (Li, Wu et al. 2010). 
Gallic acid: Gallic acid is a type of phenolic acid found in a variety of foods and herbs. 
Gallic acid is the major component of grape seed extract. The use of gallic acid can 
improve spatial learning and memory impairment for several reasons. The first reason is 
that gallic acid has antioxidant and anti-inflammatory properties (Kim, Seong et al. 
2011, Mansouri, Farbood et al. 2013, Mansouri, Naghizadeh et al. 2013, Hajipour, 
Sarkaki et al. 2016). Further, gallic acid inhibits fibril formation through the promotion 
of the non-amyloidogenic pathway by the increase of α-secretase activity and inhibits 
Aβ oligomerization (Valizadeh, Eidi et al. 2012, Liu, Pukala et al. 2013, Jayamani and 
Shanmugam 2014, Hajipour, Sarkaki et al. 2016).  
Huperzine A: Huperzine A, an alkaloid extract from Huperazia serrata is an 
antioxidant due to their ability to inhibit ROS formation and reduce lipid peroxidation 
(Xiao, Wang et al. 2000, Xiao, Zhang et al. 2002, Xiao, Zhang et al. 2002). A study 
demonstrated that huperzine A increases αAPPs release, suggesting an increase in APP 
metabolism toward the non-amyloidogenic pathway. This result suggests that huperzine 
A has a modulatory effect on α-secretase activity (Peng, Jiang et al. 2006, Peng, Lee et 
al. 2007). As a consequence, the Aβ level decrease significantly, suggesting an 
inhibitory effect of Huperzine A in Aβ production (Peng, Jiang et al. 2006).  




Kaempferol: Kaempferol is a natural polyphenolic flavonoid founded in a variety of 
fruits, vegetables, wine and tea. Studies have shown that kaempferol acts as antioxidant 
and anti-inflammatory (Marfak, Trouillas et al. 2003, Garcia-Mediavilla, Crespo et al. 
2007). One study showed that kaempferol inhibits the formation of Aβ fibrils as well as 
their extension and destabilizes preformed Aβ fibrils (Ono, Yoshiike et al. 2003). 
Probably, the inhibition of Aβ fibrils formation is caused by their capacity to inhibit Aβ 
aggregation (Akaishi, Morimoto et al. 2008). Another study reported that kaempferol is 
a β-secretase inhibitor (Shimmyo, Kihara et al. 2008). For these reasons, this 
polyphenol could be a key molecule for the development of preventives and 
therapeutics for AD. 
Luteolin: Luteolin is a natural polyphenol flavonoid that exists in many types of plants 
including fruits, vegetables, and medicinal herbs. Accumulating evidence has shown 
that luteolin exhibit potent anti-inflammatory properties and antioxidant mechanisms 
that protect against oxidative stress (Pavlica and Gebhardt 2010, Zhu, Bi et al. 2011, 
Zhao, Yao-Yue et al. 2012, Zhang, Xing et al. 2017). An experimental study discovered 
that luteolin is a potent inhibitor of β-secretase. Until the date, it is one of the most 
potent natural product inhibitors of β-secretase (Choi, Hur et al. 2008, Zheng, Yuan et 
al. 2015). Another study revealed that luteolin is able to regulate tau 
hyperphosphorylation (Zhou, Chen et al. 2012).  
Melatonin: Melatonin is an alkaloid found in animals, plants, fungi and bacteria. A 
number of experiments have shown that melatonin is a potent antioxidant due to their 
ability in neutralize oxygen-derived free radicals, reduce ROS production and scavenge 
species of other types such as carbon-centered free radicals (Daniels, van Rensburg et 
al. 1998, Pappolla, Chyan et al. 2000, Clapp-Lilly, Smith et al. 2001, Matsubara, 
Bryant-Thomas et al. 2003, Feng, Qin et al. 2006, Gunasingh, Philip et al. 2008). In 
addition, a study reported the beneficial effects of melatonin on inflammation 
(Jesudason, Baben et al. 2007). Farther, melatonin has been described as an anti-
aggregation agent. A study demonstrated that melatonin inhibits the progressive 
formation of β-sheets and amyloid fibrils, decreasing the Aβ1-42 and Aβ1-40 levels in the 
rat brains (Pappolla, Bozner et al. 1998, Poeggeler, Miravalle et al. 2001, Rudnitskaya, 
Muraleva et al. 2015). Another investigation affirmed that melatonin inhibits β- and γ-




secretase activity and PS1/PS2 but also actives the α-secretase expression thereby 
favoring the non-amyloidogenic pathway (Panmanee, Nopparat et al. 2015).  
Myricetin: Myricetin is a naturally occurring flavonoid found in many grapes, berries, 
fruits, vegetables, and herbs as well as other plants. This compound is classified as a 
strong antioxidant. Evidences revealed that myricetin is an antioxidant that prevented 
the formation of Aβ aggregates, as well as their extension, with a persistent level of 
monomes (Shimmyo, Kihara et al. 2008, Fiori, Naldi et al. 2012). These effects were 
based on two mechanisms: the activation and up-regulation of α-secretase and the 
inhibition of β-secretase (Shimmyo, Kihara et al. 2008). A high inhibitory effect of 
myricetin on fibrillogenesis of Aβ was also observed. A study demonstrated an anti-
amyloidogenic effect through the reversible binding of myricetin to fibrillar Aβ, but not 
to the monomeric species, causing Aβ conformational changes (Hirohata, Hasegawa et 
al. 2007). Additionally, this compound destabilized preformed Aβ fibrils (Ono, 
Yoshiike et al. 2003).  
Nicotine: Nicotine is an alkaloid isolated from the leaves of tobacco plant (Nicotiana 
tabacum) that affects multiple stages of amyloidogenesis in vitro. A study reported that 
nicotine may effectively reduce Aβ aggregation in brain, inhibiting the formation and 
extension of Aβ fibrils, and it was able to destabilize preformed Aβ fibrils, causing a 
significantly reduction of Aβ levels and plaque levels by more than 80%  (Nordberg, 
Hellstrom-Lindahl et al. 2002, Ono, Hasegawa et al. 2002, Srivareerat, Tran et al. 
2011). This reduction can be due to the decrease of APP (Lahiri, Utsuki et al. 2002, 
Utsuki, Shoaib et al. 2002). Nicotine retards amyloidogenesis by preventing an α-helix 
to β-sheet conformational transformation, decreasing β-secretase and PSEN1 expression 
(Salomon, Marcinowski et al. 1996, Nie, Li et al. 2011, Srivareerat, Tran et al. 2011, 
Alkadhi, Alzoubi et al. 2012). In addition to the reasons mentioned above, a different 
study suggests that the beneficial/protective effects of nicotine in AD may be, at least 
partly, due to antioxidant mechanisms (Linert, Bridge et al. 1999). 
Puerarin: Puerarin, an isoflavanone glycoside extracted from the dried roots of 
Pueraria lobata, has been reported to be useful in the treatment of various diseases. 
Studies found that puerarin had potent effects in improving spatial learning and memory 




by inhibiting the phosphorylation of tau in APP/PS1 double transgenic mice (Xu 2003, 
Zhou, Xie et al. 2014, Zhao, Yang et al. 2015, Mei, Tan et al. 2016). The anti-AD 
effects of puerarin suggested to be related to its abilities to decrease the oxidative stress 
and the neuroinflammation associated with AD (Jiang, Liu et al. 2003, Mahdy, 
Mohamed et al. 2014, Zhou, Xie et al. 2014, Zhao, Yang et al. 2015).  
Quercetin: Quercetin is a flavonol founded in fruits, vegetables, herbs, tea, and wine. 
Studies showed that quercetin decreased oxidative stress by the strong decrease of ROS 
generation and the index of lipid peroxidation (Heo and Lee 2004, Jimenez-Aliaga, 
Bermejo-Bescos et al. 2011, Ademosun, Oboh et al. 2016). Moreover, quercetin 
disaggregated Aβ fibrils, transforming the fibrils into amorphous aggregates (Wang, 
Wang et al. 2011). Quercetin, by specifically activating macroautophagy and 
proteasomal degradation pathways, proved to be able to prevent Aβ1-42 aggregation, 
inhibiting the formation of Aβ fibrils and reducing brain Aβ levels in amyloid model 
mice (5xFAD) (Jimenez-Aliaga, Bermejo-Bescos et al. 2011, Regitz, Dussling et al. 
2014, Zhang, Hu et al. 2016). Additionally, this compound is a natural β-secretase 
inhibitor (approximately 20–30%) and can attenuate tau hyperphosphorylation 
(Shimmyo, Kihara et al. 2008, Chen, Deng et al. 2016).  
Resveratrol: Resveratrol is a natural non-flavonoid polyphenol founded in high 
concentrations in grapes (Vitis vinifera L. (Vitaceae)). Studies showed that resveratrol 
markedly slow down the formation of Aβ fibrils and their extension by disrupting Aβ1-42 
hydrogen bonding and promote intracellular degradation of Aβ aggregates and 
preformed Aβ1-42 fibrils in vitro through promotion of intracellular proteosomal activity 
(Marambaud, Zhao et al. 2005, Feng, Wang et al. 2009). Also in vitro studies showed 
that resveratrol interfere in Aβ1-42 aggregation, retarding or even inhibiting the 
aggregation of Aβ, and change the Aβ1-42 oligomers conformation (Feng, Wang et al. 
2009, Loureiro, Andrade et al. 2017). Resveratrol selectively remodels three of 
conformers (soluble oligomers, fibrillar intermediates, and amyloid fibrils) into an 
alternative aggregated species that are non-toxic, high molecular weight, and 
unstructured (Ladiwala, Lin et al. 2010). Besides that, resveratrol reduced the insoluble 
Aβ1-42 level in hippocampus and plaque formation in medial cortex (-48%), striatum (-
89%) and hypothalamus (-90%) (Karuppagounder, Pinto et al. 2009, Zhao, Li et al. 




2015). A study suggests that resveratrol reduces the Aβ levels by promoting a non-
amyloidogenic processing of APP (Marambaud, Zhao et al. 2005). In addition, 
resveratrol exerts anti-inflammatory and antioxidant effects (Fremont 2000, Kumar, 
Naidu et al. 2007, de Almeida, Leite et al. 2008, Gong, Li et al. 2010, Lu, Ma et al. 
2010, Ma, Sun et al. 2013, Rege, Geetha et al. 2015, Moussa, Hebron et al. 2017). 
Specifically, it scavenges ROS and up-regulates cellular antioxidants including 
glutathione (Jang and Surh 2003, Granzotto and Zatta 2011). Lastly, resveratrol can 
inhibits tau hyperhosphorylation (He, Li et al. 2017). 
Retinoic acid: In similarity with retinal, retinoic acid is also a naturally occurring 
terpenoid, a metabolite of vitamin A reported to have anti-aggregation activity and Aβ 
fibrils clearance activity (Ono, Yoshiike et al. 2004). Retinoic acid can suppress the 
production of Aβ through direct inhibition of β- and γ-secretase activity and the 
promotion of α-secretase activity (Koryakina, Aeberhard et al. 2009, Tippmann, Hundt 
et al. 2009, Kapoor, Wang et al. 2013).  
Salvianolic acid B: Salvianolic acid B is a phenylpropanol isolated from the root of 
Salvia miltiorrhiza, a Chinese herbal medicine. Salvianolic acid B is a promising agent 
in treatment of neurodegenerative diseases. Studies demonstrated that salvianolic acid B 
is a potent natural antioxidant, which could scavenge superoxide anion, ROS and 
hydroxyl radicals and inhibit lipid peroxidation (Huang and Zhang 1992). This 
compound can significantly suppress the accumulation of Aβ, inhibit Aβ aggregation, 
thereby preventing the formation of Aβ and disaggregate Aβ fibrils (Tang and Zhang 
2001, Durairajan, Yuan et al. 2008, Cheng, Gong et al. 2013). A study suggests that 
salvianolic acid B is a promising therapeutic agent for AD by inhibiting Aβ generation 
by suppressing β-secretase (Tang, Huang et al. 2016). 
Vitamin C: The richest natural sources of vitamin C are fruits and vegetables, and of 
those, the Kakadu plum and the camu camu fruit contain the highest concentration. Data 
showed that individuals with lower plasma vitamin C values are at high risk for 
developing AD (Helmer, Peuchant et al. 2003). Several studies conducted in mice 
reported that vitamin C prevented brain oxidative damage through their potent 
antioxidant activity for neutralizing free radicals (Tabet, Mantle et al. 2002, Choi, 




Conrad et al. 2003, Martin 2003, Ho and Chang 2004, Sil, Ghosh et al. 2016). A study 
reported that vitamin C attenuated Aβ oligomers formation and behavioral decline in an 
AD mouse model. The attenuation of Aβ oligomerization was accompanied with a 
marked decrease in the ratio of soluble Aβ1-42 to Aβ1-40 (Murakami, Murata et al. 2011). 
In addition, the high supplementation of vitamin C resulted in the reduction of Aβ 
plaque burden in the cortex and hippocampus in mice with AD (Kook, Lee et al. 2014).  
Vitamin E: The vitamin E is present in several fruits and vegetables including wheat 
germ and almond oils. It was observed that the risk for developing AD increases in 
individual with lower plasma vitamin E values (Helmer, Peuchant et al. 2003). Studies 
showed that vitamin E acts as a major chain-breaking lipid soluble antioxidant 
responsible for blocking lipidic peroxidation. It also appears to have the function of 
scavenging free Aβ-associated radicals (Subramaniam, Koppal et al. 1998, Butterfield, 
Koppal et al. 1999, Yatin, Yatin et al. 1999). Conducted trials in mice proved that 
pretreatment with vitamin E prevented brain oxidative damage (Choi, Conrad et al. 
2003, Giraldo, Lloret et al. 2014). Besides that, vitamin E possesses anti-inflammatory 
activity (Rosales-Corral, Tan et al. 2003). Other study using a transgenic model of AD  
(Tg2576) revealed that when vitamin E was administered at a young age showed a 
significant reduction in Aβ levels and amyloid deposition, reducing neuronal injuries 













Table 1 - Natural products with neurological activities, their typical origin and their mode of action. 




Antioxidant; Anti-inflammatory; Inhibition of 
β-secretase; Inhibition of Aβ deposition 
Asiatic acid Centella asiatica 
Antioxidant; Inhibition of β-secretase; 




Antioxidant; Activation of α-secretase; 
Inhibition of β-secretase; Inhibition of Aβ 
fibrillation, Aβ oligomerization and Aβ 
aggregation; Clearance of Aβ fibrils; Inhibition 
of tau hyperphosphorylation 
Berberine Rhizoma coptidis 
Antioxidant; Anti-inflammatory; Inhibition of 






Antioxidant; Anti-inflammatory; Inhibition of 
β and γ-secretase; Aβ clearance; Inhibitor of β-






Antioxidant; Anti-inflammatory; Inhibition of 
Aβ aggregation; Clearance of Aβ aggregates 
Crocin Crocus sativus 
Antioxidant; Anti-inflammatory; Inhibition of 
Aβ fibrils formation; Clearance of Aβ 
aggregates 
Curcumin Curcuma longa 
Antioxidant; Anti-inflammatory; Inhibition of 
β-and γ-secretase; Inhibition of Aβ fibrillation; 
Inhibition of Aβ aggregation; Inhibition of Aβ 
fibril formation; Inhibition of Aβ plaques 
formation; Clearance of Aβ fibrils; Inhibition 
of tau hyperphosphorylation 
   
   




Compound Typical origin Mechanism of action 
Docosahexaenoic 
acid 
Marine fish and 
algae 
Antioxidant; Inhibition of β- and γ-secretase; 
Activation of α-secretase; Inhibition of Aβ 
fibril formation, Aβ fibrillation and Aβ 




Antioxidant; Anti-inflammatory; Inhibition of 
β- and γ-secretase; Activation of α-secretase; 
Inhibition of Aβ fibrillation and Aβ 
oligomerization; Clearance of Aβ fibrils; 
Inhibition of tau hyperphosphorylation; 
Inhibition of tau aggregation; Clearance of tau 
fibrils 
Ferulic acid Ferula communis 
Antioxidant; Inhibition of β-secretase; 
Inhibition of Aβ fibrillation and Aβ 
aggregation; Clearance of Aβ fibrils 
Fisetin Rhus succedanea 
Antioxidant; Anti-inflammatory; Inhibition of 






Antioxidant; Anti-inflammatory; Inhibition of 
β-secretase; Inhibition of Aβ deposition; 
Inhibition of Aβ aggregation; Inhibition of Aβ 




Antioxidant; Anti-inflammatory; Activation of 
α-secretase; Inhibition of Aβ oligomerization 




Antioxidant; Anti-inflammatory; Inhibition of 
β-secretase; Inhibition of Aβ aggregation; 
Clearance of Aβ fibrils 
Luteolin Perilla frutescens 
Antioxidant; Anti-inflammatory; Inhibition of 
β-secretase; Inhibition of tau 
hyperphosphorylation 
   







Compound Typical origin Mechanism of action 
Melatonin Pineal glands 
Antioxidant; Anti-inflammatory; Inhibition of 
β- and γ-secretase; Activation of α-secretase; 





Antioxidant; Inhibition of β-secretase; 
Activation of α-secretase; Inhibition of Aβ 




Antioxidant; Inhibition of β-secretase; 
Inhibition of Aβ aggregation and β-sheet 
formation; Clearance of Aβ fibrils 
Puerarin Pueraria lobata 
Antioxidant; Anti-inflammatory; Inhibition of 
tau hyperphosphorylation 
Quercetin Apple 
Antioxidant; Inhibition of β-secretase; 
Inhibition of Aβ aggregation; Clearance of Aβ 
fibrils; Inhibition of tau hyperphosphorylation 
Resveratrol Vitis vinifera 
Antioxidant; Anti-inflammatory; Activation of 
α-secretase; Inhibition of Aβ aggregation; 
Inhibition of Aβ conformation; Clearance of 
Aβ; Inhibition of tau hyperphosphorylation 
Retinoic acid Carotenoids 
Inhibition of β- and γ-secretase; Activation of 
α-secretase; Inhibition of Aβ aggregation; 
Clearance of Aβ fibrils 
Salvianolic acid B 
Salvia 
miltiorrhiza 
Antioxidant; Inhibition of β-secretase; 
Inhibition of Aβ accumulation; Inhibition of 
Aβ aggregation; Clearance of Aβ fibrils 
Vitamin C Kakadu plum 
Antioxidant; Inhibition of Aβ oligomers 
formation 
Vitamin E Wheat germ oil Antioxidant; Anti-inflammatory 





AD is known as the most important neurodegenerative disease and the most common 
cause of dementia among the elderly.  This disease is multifactorial and incapacitating 
that deprives patients of basic cognitive functions, culminating in a state of dementia 
and complete loss of independence. At the moment, no pharmacologically effective 
treatment to stop or cure the progression of AD has been developed. With the increase 
of average life expectancy, the discovery and development of new drugs to treat AD is 
highly demanding. 
The potential of natural products for the prevention and cure of AD is supported by the 
literature. The majority of natural compounds studied to date with a direct relevance to 
AD are mainly from plants, with comparatively few molecules derived from marine and 
microbial sources. As multiple causative factors exist for the pathology of AD, various 
mechanisms may be associated with the preventative effects and treatment. Most of 
these natural products are rich in polyphenols and have been preferably studied due to 
their multiple functions (such antioxidant and anti-inflammatory properties). Therefore, 
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